The COVID-19 pandemic demonstrated how faster approval processes and other thoughtful reforms can help patients, while still adhering to strict safety and quality standards. The Coronavirus Treatment Acceleration Program (CTAP), Operation Warp Speed, and the use of Emergency Use Authorizations (EUA) were commendable. It’s now time to build on that foundation to crystallize COVID’s lessons for future pandemics by implementing key reforms at the Food and Drug Administration.
Read the full story here.